The fentanyl crisis is loosening its grip on America's workforce—but employers aren't off the hook yet. With opioids still killing nearly 44,600 people in 2025, the Department of Labor just told businesses to gear up for workplace overdoses.
The numbers are still ugly. Quest Diagnostics data shows almost 20 percent of employees tested positive for illicit substances in 2025—a 46 percent jump from 2021, driven by cocaine, meth, and amphetamines. Marijuana dominated the results, accounting for more than 53 percent of all positives, as legalization spreads faster than companies update their drug policies.
But here's the win: fentanyl detection among workers dropped by nearly half year-over-year—0.55 percent in 2024 to 0.28 percent in 2025. Quest credits employers' expanded testing, education, and deterrence efforts.
The risk hasn't vanished. Opioids killed 44,564 people in 2025, down from nearly 70,000 the year before—but EMS was called to over 12,600 potential workplace overdoses in 2024. And fentanyl shows up in random testing at rates up to 707 percent higher than pre-employment screens, meaning current employees are the bigger blind spot.
Most businesses aren't ready. A 2024 National Safety Council survey found 62 percent of employers worried about opioid use on the job—yet only 30 percent said their company stocked opioid reversal medications.
The DOL's fix: treat naloxone and nalmefene like defibrillators—standard emergency equipment, on hand at every site, with workers trained to spot overdose signs (slow breathing, blue lips, pinpoint pupils, unresponsiveness) and act fast.
"Fentanyl acts as a chemical weapon against our people," said White House drug czar Sara Carter. "It is critically important that the American workforce is familiar with drug overdose recognition and reversal."
The takeaway: the fentanyl tide is turning, but until it's gone, naloxone in the break-room cabinet could be the difference between a close call and a tragedy.